加味宣白承气汤联合噻托溴铵治疗哮喘慢阻肺重叠综合征临床研究

Clinical Study of Modified Xuanbai Chengqi Decoction(加味宣白承气汤)Combined with Tiotropium Bromide in Treatment of ACOS

目的探讨加味宣白承气汤联合噻托溴铵治疗哮喘慢阻肺重叠综合征(ACOS)临床疗效。方法选取该院2020年5月—2021年5月期间收治的100例ACOS患者为研究对象,将其随机分为对照组48例和观察组52例,对照组给予噻托溴铵治疗,观察组在上述基础联合加味宣白承气汤治疗,连续治疗4周,比较两组患者哮喘症状评分(ACT)、慢性阻塞性肺疾病症状评分(CAT)评分、肺功能、血氧状态。结果治疗前,两组患者ACT、CAT评分比较无明显差异(P>0.05),治疗后,两组患者ACT评分升高、CAT评分下降,且观察组优于对照组(P<0.05);治疗前,两组患者1秒用力呼气量(FEV_(1))、FEV_(1)/用力肺活量(FVC)、呼气峰值流速(PEFR)比较无统计学意义(P>0.05),治疗后,两组患者上述肺功能指标均升高,且观察组大于对照组(P<0.05);治疗前,两组患者氧分压(PaO_(2))、二氧化碳分压(PaCO_(2))比较无显著差异(P>0.05),治疗后,两组患者PaO_(2)升高、PaCO_(2)下降,且观察组优于对照组(P<0.05);两组患者在治疗期间均未发生恶心、呕吐、肝肾功能损害等不良反应。结论ACOS患者应用加味宣白承气汤联合噻托溴铵治疗,临床效果佳,可有效缓解临床症状,促进肺功能及血氧状态的改善,且安全性较高。

Objective To investigate the clinical effect of Modified Xuanbai Chengqi Decoction(加味宣白承气汤)combined with tiotropium bromide in the treatment of asthma-chronic obstructive pulmonary disease overlap syndrome(ACOS).Methods A total of 100 patients with ACOS admitted to the hospital from May 2020 to May 2021 were selected as the research subjects,and randomly divided into control group 48 cases and observation group 52 cases.Patients in control group were treated with tiotropium bromide,while those in observation group were treated with Modified Xuanbai Chengqi Decoction combined with tiotropium bromide.Both groups were given 4 weeks of treatment.The Asthma Control Test(ACT)score,COPD Assessment Test(CAT)score,pulmonary function and blood oxygen status were compared between the two groups.Results After treatment,the ACT scores were increased and the CAT scores were reduced in the two groups.The above scores of the observation group were better than those of the control group(P<0.05).After treatment,the forced expiratory volume in the 1^(st) second(FEV_(1)),FEV_(1)/forced vital capacity(FVC)and peak expiratory flow rate(PEFR)were increased in the two groups,which were higher in the observation group than those in the control group(P<0.05).After treatment,the partial pressure of oxygen(PaO_(2))was increased and the partial pressure of carbon dioxide(PaCO_(2))was reduced in the two groups.The blood oxygen status of the observation group was better than that of the control group(P<0.05).No adverse reactions such as nausea,vomiting,liver and kidney damage were observed in the two groups during the treatment.Conclusion Modified Xuanbai Chengqi Decoction combined with tiotropium bromide is effective in the treatment of patients with ACOS,which can effectively relieve clinical symptoms and promote the improvement of lung function and blood oxygen status,with high safety.